Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
R.M. Shaginian
Observed names:
R. M. Shaginian,
R. Shaginian,
RM Shaginian,
Shaginian, R.,
Shaginian, R.M.
Institution:
Eli Lilly (Netherlands)
Observed institution:
Eli Lilly (Netherlands)
OpenAlex ID:
A5111844527
Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetes
2011
·
M. C. Bunck
, B. Eliasson
, et al.
·
Diabetes Obesity and Metabolism
·
116
Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide
2015
·
G. Grunberger
, T. Forst
, et al.
·
Diabetic Medicine
·
11
Three-year exenatide therapy, followed by a 4-week off-drug period, had a sustainable effect on beta-cell disposition index in metformin treated patients with type 2 diabetes
2010
·
Bunck, M.C.M.
, Corner, A.
, et al.
·
Pure Amsterdam UMC
·
4
Beneficial Changes on Body Composition and Circulating Adiponectin and hsCRP Levels Following One Year of Exenatide Therapy, Compared with Insulin Glargine, in Metformin-Treated Patients with Type 2 Diabetes
2009
·
Bunck, M.C.M.
, Diamant, M.
, et al.
·
Pure Amsterdam UMC
·
3
Extended, 3-year, exenatide therapy shows sustainable effects on beta cell disposition index in metformin treated patients with type 2 diabetes
2010
·
Bunck, M.C.M.
, Corner, A.
, et al.
·
Pure Amsterdam UMC
·
2
One Year Exenatide Therapy, Compared with Insulin Glargine, Reduces Postprandial Oxidative Stress in Metformin-Treated Patients with Type 2 Diabetes
2009
·
Bunck, M.C.M.
, Corner, A.
, et al.
·
Pure Amsterdam UMC
·
2
One-year exenatide treatment improves beta cell response in metformin treated patients with type 2 diabetes which is sustained after 5 weeks discontinuation of treatment
2009
·
Bunck, M.C.M.
, Mari, A.
, et al.
·
Pure Amsterdam UMC
·
1
O28 Efficacité et sécurité du dulaglutide en administration hebdomadaire et de l’insuline glargine en administration quotidienne à 52 semaines de traitement chez les patients diabétiques de type 2 (DT2) inclus dans l’étude AWARD-2 (Assesment of Weekly Adminis)
2015
·
J. Vora
, O. Adetunji
, et al.
·
Diabetes & Metabolism
Op8 the 2-week Fasting Glucose as a Predictor of Glycemic Response to Once-weekly Dulaglutide 1.5 Mg
2014
·
S. Gough
, G. Grunberger
, et al.
·
Diabetes Research and Clinical Practice
Glycaemic control and hypoglycaemia in metformin-treated T2DM patients with exenatide BID vs insulin lispro TID added to titrated insulin glargine QD: the 4B trial
2013
·
Wolffenbuttel, B. H. R.
, Nauck, M. A.
, et al.
·
University of Groningen research database (University of Groningen / Centre for Information Technology)
Bone mineral density was not affected by exenatide therapy despite a significant reduction in body weight in patients with type 2 diabetes
2010
·
Eliasson, B.
, Bunck, M.C.M.
, et al.
·
Pure Amsterdam UMC
Verbesserung von Betazellfunktion und glykämischer Kontrolle nach einem Jahr Therapie mit Exenatide bei Metformin-behandelten Patienten mit Typ-2-Diabetes
2008
·
O Bachmann
, C Kazda
, et al.
·
Diabetologie und Stoffwechsel
Show more works
View as search
Works count:
12
Citation count:
139
H-index:
3
I10-index:
2
Year
Topic
Type